全文获取类型
收费全文 | 41947篇 |
免费 | 4591篇 |
国内免费 | 847篇 |
专业分类
耳鼻咽喉 | 302篇 |
儿科学 | 876篇 |
妇产科学 | 547篇 |
基础医学 | 3146篇 |
口腔科学 | 1497篇 |
临床医学 | 4092篇 |
内科学 | 5312篇 |
皮肤病学 | 468篇 |
神经病学 | 3252篇 |
特种医学 | 1262篇 |
外国民族医学 | 3篇 |
外科学 | 3350篇 |
综合类 | 4745篇 |
现状与发展 | 5篇 |
一般理论 | 2篇 |
预防医学 | 7113篇 |
眼科学 | 566篇 |
药学 | 3382篇 |
25篇 | |
中国医学 | 4411篇 |
肿瘤学 | 3029篇 |
出版年
2024年 | 38篇 |
2023年 | 929篇 |
2022年 | 908篇 |
2021年 | 1637篇 |
2020年 | 1741篇 |
2019年 | 1702篇 |
2018年 | 1690篇 |
2017年 | 1613篇 |
2016年 | 1477篇 |
2015年 | 1318篇 |
2014年 | 3108篇 |
2013年 | 3171篇 |
2012年 | 2514篇 |
2011年 | 2672篇 |
2010年 | 2044篇 |
2009年 | 1956篇 |
2008年 | 2217篇 |
2007年 | 2285篇 |
2006年 | 2037篇 |
2005年 | 1708篇 |
2004年 | 1409篇 |
2003年 | 1345篇 |
2002年 | 1043篇 |
2001年 | 959篇 |
2000年 | 760篇 |
1999年 | 650篇 |
1998年 | 450篇 |
1997年 | 466篇 |
1996年 | 361篇 |
1995年 | 412篇 |
1994年 | 360篇 |
1993年 | 302篇 |
1992年 | 299篇 |
1991年 | 268篇 |
1990年 | 225篇 |
1989年 | 207篇 |
1988年 | 196篇 |
1987年 | 156篇 |
1986年 | 124篇 |
1985年 | 115篇 |
1984年 | 102篇 |
1983年 | 71篇 |
1982年 | 67篇 |
1981年 | 61篇 |
1980年 | 59篇 |
1979年 | 32篇 |
1978年 | 29篇 |
1977年 | 28篇 |
1976年 | 18篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
101.
102.
Tomotaka Shingaki Kentaro Taki Momoha Koyanagi Soshi Nagaoka Kenichi Yoshizawa Norika Oki 《Current medical research and opinion》2020,36(6):947-958
AbstractObjective: To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice.Methods: This prospective, non-interventional, multicenter, observational, post-marketing safety study (PMSS) enrolled Japanese patients with type 1 or 2 diabetes mellitus (T1DM or T2DM) starting GLY therapy, and was required by Japanese Pharmaceutical Affairs Law mandating post-marketing safety surveillance to acquire safety and effectiveness data of biosimilar products. Data collected from the 12-month observation included patient characteristics, adverse events, and blood glucose control.Results: The study enrolled 141 patients with T1DM and 1104 patients with T2DM. Pre-study insulin was used by 94.1% of patients with T1DM and 75.0% with T2DM. 65.4% of patients with T1DM and 64.3% with T2DM switched from the reference product (GLY-switched), while 25.0% with T2DM were insulin-naive. Adverse events were reported by 5.7% and 8.5% in T1DM and T2DM, respectively. Similar incidences were reported in GLY-switched. Adverse events were reported by 10.7% in insulin-naive T2DM. Baseline mean hypoglycemic events/month were 1.8 and 0.1 in T1DM and T2DM, respectively: the mean change from baseline (CFB) was –1.2 (p?=?.066) and 0.0 (p?=?.915), respectively. Baseline mean HbA1c was 8.4% and 8.7% in T1DM and T2DM, respectively; the mean CFB was –0.5% (p?<?.001) and –0.9% (p?<?.001), respectively, and –1.5% (p?<?.001) in insulin-naive T2DM.Conclusions: This first long-term Japanese PMSS of GLY demonstrated adverse events, hypoglycemia, and glycemic control consistent with the known GLY profile for T1DM and T2DM patients, in routine clinical practice. 相似文献
103.
104.
目的 解析真实世界中乳腺恶性肿瘤患者的人群特征、诊断特征、中西医用药特征,为乳腺癌的临床防治提供参考。方法 采集2002年2月至2015年5月全国60家三级甲等医 院信息系统(Hospital Information System,HIS)中,出院诊断为“乳腺癌”的患者用药信息,采用SAS9.3统计软件,对人口学信息、诊断信息、医嘱用药信息等进行描述性分析。结果 39798例乳腺癌患者,平均年龄(50.93者,平均年龄)岁;多以门诊入院,入院病情以“一般”为主;合并疾病主要为高血压,骨肿瘤,联用西药以抑制肿瘤细胞增殖、治疗并发症、缓解放化疗不良反应为主;中医辨证以痰瘀互结证,气阴两虚证,肝气淤滞证,脾气亏虚证型最为常见,临床清热解毒剂、益气扶正剂,活血化瘀剂应用较多。结论 乳腺癌中西医结合治疗,联用药物广泛,临床治疗基本符合临床指南。 相似文献
105.
《Clinical breast cancer》2020,20(1):80-86
BackgroundEpidermal growth factor receptor (EGFR) is frequently overexpressed in metastatic triple-negative breast cancer (mTNBC). One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. The antidiabetic drug metformin inhibits both MAPK and PI3K/mTOR pathway signaling. We evaluated the combination of erlotinib and metformin in a phase 1 study of patients with mTNBC.Patients and MethodsPatients with mTNBC who had received at least one prior line of therapy for metastatic disease were eligible. Erlotinib dose was fixed at 150 mg daily. Metformin dose escalation was planned according to a 3 + 3 design. Dose-limiting toxicities (DLT) were assessed during the first 5 weeks of therapy. The primary objective was to determine the maximum tolerated dose of metformin with fixed-dose erlotinib. Secondary endpoints were response rate, stable disease rate, and progression-free survival.ResultsEight patients were enrolled. The median number of prior therapies for metastatic disease was 2.5 (range, 1-6). No DLT events were reported during the DLT assessment period. Most adverse events were grade 1/2. Grade 3 diarrhea despite maximum supportive care required dose reduction of metformin in one patient. Grade 3 rash led to study withdrawal in one patient. No grade 4 adverse events were reported. The best observed response was stable disease in 2 patients (25%). Median progression-free survival was 60 days (range, 36-61 days).ConclusionErlotinib and metformin were well tolerated in a population of pretreated mTNBC patients but did not demonstrate efficacy in this population. 相似文献
106.
目的:基于文献整理探讨中医药治疗系统性红斑狼疮(Systemic lupus erythematosus,SLE)的证候分类及用药规律演变。方法:检索中国知网(CNKI)、维普中文科技期刊数据库、中国学术期刊数据库中中医药治疗SLE的相关文献,时间限定为从数据库建立至2018年7月。对证型及药物进行分类并统计分析。结果:纳入文献725篇,总结归纳高频证型11个,出现频次最高的五个证型分别为热毒炽盛证、脾肾两(阳)虚证、阴虚内热(火旺)证、肝肾两(阴)虚证、气阴两虚证,累计频率62.11%。1965-2018年间,阴虚内热(火旺)证呈明显增长趋势;热毒炽盛证、脾肾两(阳)虚证及气阴两虚证在1965-2010年间呈增长趋势,在2011-2018年间呈下降趋势;肝郁气滞(脾虚)证在1965-2018年间呈下降趋势;其余证型均呈动态波动。涉及组方1522个,药物309味,使用15910次,总使用频率最高的5味药分别为生地黄、牡丹皮、茯苓、黄芪、甘草,总累计频率16.42%。使用频率最高药类为清热药和补虚药;生地黄、牡丹皮等清热药的使用频率趋势与热毒炽盛证保持一致,不同年份高频用药大致相似,用药频率存在较小差异。结论:SLE在内以阴阳亏虚为主,在外与热毒侵袭相关,属于本虚标实,其发展与生态环境、社会环境、药物使用等紧密相关,治当以清热凉血、活血祛瘀、益气养阴,并结合个人体质及环境变化辨证治疗。 相似文献
107.
目的:评价芪胶升白胶囊治疗癌因性气血两虚证的临床疗效。方法:选取2016年3月至2018年3月8个医疗中心拟行化疗的气血两虚证肺癌及乳腺癌患者312例作为研究对象。采用中央随机法,受试者按2∶1随机进入观察组或对照组。观察组口服芪胶升白胶囊,对照组口服安多霖胶囊,2组患者均口服包装编盲药物,4粒/次,3次/d,疗程均为20 d(1个化疗周期)。主要疗效指标为气血两虚证候总积分改善率,次要疗效指标包括单项症状改善率、治疗前后证候积分差值。结果:共纳入309例癌因性气血两虚证患者,符合方案集(PPS)共266例(观察组185例、对照组81例)。2组患者气血两虚证候总积分均较治疗前明显下降,2组证候总积分改善率差异无统计学意义(P>0.05)。观察组心悸失眠单项症状改善率优于对照组(P<0.05)。2组均未发生严重不良反应。结论:芪胶升白胶囊能有效治疗癌因性气血两虚证,可有效防治化疗进一步耗伤气血。 相似文献
108.
Shahrzad Ghafary Roshanak Ghobadian Mohammad Mahdavi Hamid Nadri Alireza Moradi Tahmineh Akbarzadeh Zahra Najafi Mohammad Sharifzadeh Najmeh Edraki Farshad Homayouni Moghadam Mohsen Amini 《Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences》2020,28(2):463
BackgroundAcetylcholine deficiencies in hippocampus and cortex, aggregation of β-amyloid, and β-secretase over activity have been introduced as main reasons in pathogenesis of Alzheimer’s disease.MethodsColorimetric Ellman’s method was used for determination of IC50 value in AChE and BChE inhibitory activity. The kinetic studies, neuroprotective and β-secretase inhibitory activities, evaluation of inhibitory potency on β-amyloid (Aβ) aggregations induced by AChE, and docking study were performed for prediction of the mechanism of action.Result and discussionA new series of cinnamic acids-tryptamine hybrid was designed, synthesized, and evaluated as dual cholinesterase inhibitors. These compounds demonstrated in-vitro inhibitory activities against acetyl cholinesterase (AChE) and butyryl cholinesterase (BChE). Among of these synthesized compounds, (E)-N-(2-(1H-indol-3-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide (5q) demonstrated the most potent AChE inhibitory activity (IC50 = 11.51 μM) and (E)-N-(2-(1H-indol-3-yl)ethyl)-3-(2-chlorophenyl)acrylamide (5b) were the best anti-BChE (IC50 = 1.95 μM) compounds. In addition, the molecular modeling and kinetic studies depicted 5q and 5b were mixed type inhibitor and bound with both the peripheral anionic site (PAS) and catalytic sites (CAS) of AChE and BChE. Moreover, compound 5q showed mild neuroprotective in PC12 cell line and weak β-secretase inhibitory activities. This compound also inhibited aggregation of β-amyloid (Aβ) in self-induced peptide aggregation test at concentration of 10 μM.ConclusionIt is worth noting that both the kinetic study and the molecular modeling of 5q and 5b depicted that these compounds simultaneously interacted with both the catalytic active site and the peripheral anionic site of AChE and BChE. These findings match with those resulted data from the enzyme inhibition assay. Graphical abstractOpen in a separate windowA new series of cinnamic-derived acids-tryptamine hybrid derivatives were designed, synthesized and evaluated as butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) inhibitors and neuroprotective agents. Compound 5b and 5q, as the more potent compounds, interacted with both the peripheral site and the choline binding site having mixed type inhibition. Results suggested that derivatives have a therapeutic potential for the treatment of AD.Electronic supplementary materialThe online version of this article (10.1007/s40199-020-00346-9) contains supplementary material, which is available to authorized users. 相似文献
109.
《Biomedical and environmental sciences : BES》2020,33(1):1-10
Objective To estimate the burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China.Methods Data from the Global Burden of Disease Study 2016(GBD 2016) were used. We evaluated the burden by analyzing age-sex-province-specific prevalence, mortality, and disability-adjusted lifeyears(DALYs) of 33 provinces in China.Results From 1990 to 2016, prevalence cases in thousands increased by 73.7% from 6833.3(95% UI:6498.0–7180.6) to 11869.6(95% UI: 11274.6–12504.7). Age-standardized mortality and DALY rates per100,000 decreased by 51.2% and 53.3%, respectively. Male and elderly people(aged ≥ 60 years)preponderance were found for prevalence, mortality, and DALYs. The number of prevalence cases,deaths, and DALYs due to hepatitis C virus(HCV) increased by 86.6%, 8.7%, and 0.9%, respectively. Also,age-standardized prevalence rates decreased in 31 provinces, but increased in Yunnan and Shandong.The Socio-demographic Index(SDI) values were negatively correlated with age-standardized mortality and DALY rates by provinces in 2016; the correlation coefficients were-0.817 and-0.828, respectively.Conclusion Cirrhosis and other chronic liver diseases remain a huge health burden in China, with the increase of population and the aging of population. Hepatitis B virus(HBV) remains the leading cause of the health burden in China. 相似文献
110.